Abstract
With the advent of highly active antiretroviral therapy (HAART), the reduction in overall mortality and morbidity in HIV patients has been accompanied by the emergence of liver disease as a leading cause of death. Elevated liver enzymes may be due to HAART or to other risk factors, including hepatitis co-infection and alcohol use. The different components of HAART are each associated with different risks of liver toxicity. Most drugs are metabolized by cytochrome P450 enzymes in the liver, and this may be affected by liver disease. The mechanisms for drug-induced liver injury include dose-dependent toxicity, hypersensitivity reactions, idiosyncratic reactions, mitochondrial toxicity, and immune reconstitution. The diagnosis of drug-induced liver injury is exclusionary. Once diagnosed, management generally involves discontinuation of the offending drug(s). A number of studies in progress are investigating whether treatment of hepatitis co-infection can improve the tolerability of HAART.
Keywords: Highly active antiretroviral therapy, liver injury, hepatitis co-infection
Current Drug Safety
Title: Highly Active Antiretroviral Therapy-Induced Liver Injury
Volume: 3 Issue: 1
Author(s): Maurizio Bonacini and Ira Inductivo-Yu
Affiliation:
Keywords: Highly active antiretroviral therapy, liver injury, hepatitis co-infection
Abstract: With the advent of highly active antiretroviral therapy (HAART), the reduction in overall mortality and morbidity in HIV patients has been accompanied by the emergence of liver disease as a leading cause of death. Elevated liver enzymes may be due to HAART or to other risk factors, including hepatitis co-infection and alcohol use. The different components of HAART are each associated with different risks of liver toxicity. Most drugs are metabolized by cytochrome P450 enzymes in the liver, and this may be affected by liver disease. The mechanisms for drug-induced liver injury include dose-dependent toxicity, hypersensitivity reactions, idiosyncratic reactions, mitochondrial toxicity, and immune reconstitution. The diagnosis of drug-induced liver injury is exclusionary. Once diagnosed, management generally involves discontinuation of the offending drug(s). A number of studies in progress are investigating whether treatment of hepatitis co-infection can improve the tolerability of HAART.
Export Options
About this article
Cite this article as:
Bonacini Maurizio and Inductivo-Yu Ira, Highly Active Antiretroviral Therapy-Induced Liver Injury, Current Drug Safety 2008; 3 (1) . https://dx.doi.org/10.2174/157488608783333916
DOI https://dx.doi.org/10.2174/157488608783333916 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
G Protein-Activated Inwardly Rectifying Potassium Channels as Potential Therapeutic Targets
Current Pharmaceutical Design Cell Death and Survival Through the Endoplasmic Reticulum- Mitochondrial Axis
Current Molecular Medicine Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today:Glucagon-Like Peptide-1 (GLP-1) and Glucose-ependent Insulinotropic Polypeptide (GIP)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Late Sodium Current is a New Therapeutic Target to Improve Contractility and Rhythm in Failing Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Xenosensors CAR and PXR at Work: Impact on Statin Metabolism
Current Drug Metabolism Beta-2 Agonists in Asthma: Medicine or Murderer?
Current Respiratory Medicine Reviews Review on Documented Medicinal Plants used for the Treatment of Cancer
Current Traditional Medicine Transient Receptor Potential (TRP) Channels and Cardiac Fibrosis
Current Topics in Medicinal Chemistry Tolerability of Amine Uptake Inhibitors in Urologic Diseases
Current Drug Safety Pharmacotherapy for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease
Current Alzheimer Research Cardiac Tissue Engineering
Recent Patents on Regenerative Medicine Building A New Treatment For Heart Failure-Transplantation of Induced Pluripotent Stem Cell-derived Cells into the Heart
Current Gene Therapy Calcium Homeostasis and Kinetics in Heart Failure
Medicinal Chemistry Aetiology, Diagnosis and Treatment of Hydrops Foetalis
Current Pediatric Reviews Old and New Antiepileptic Drugs for the Treatment of Idiopathic Generalized Epilepsies
Current Clinical Pharmacology Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Vitamins and Cognition: A Nutrigenomics Perspective
Current Nutrition & Food Science Emerging Concepts for Myocardial Late Gadolinium Enhancement MRI
Current Cardiology Reviews Asymmetric Dimethylarginine (ADMA): A Promising Biomarker for Cardiovascular Disease?
Current Topics in Medicinal Chemistry